Skip to search form
Skip to main content
Skip to account menu
Semantic Scholar
Semantic Scholar's Logo
Search 231,119,072 papers from all fields of science
Search
Sign In
Create Free Account
avasimibe
Known as:
2,6-bis(1-methylethyl)phenyl ((2,4,6-tris(1-methylethyl)phenyl)acetyl)sulfamate
An orally bioavailable inhibitor of acyl-Coenzyme A:cholesterol acyltransferase (ACAT) that prevents cholesterol deposition in the arterial wall…
Expand
National Institutes of Health
Create Alert
Alert
Related topics
Related topics
4 relations
Broader (3)
Acetates
Cytochrome P-450 CYP3A Inducers
Sulfonic Acids
Narrower (1)
CI 1011
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
2009
2009
Novel 1,4-diarylpiperidine-4-methylureas as anti-hyperlipidemic agents: dual effectors on acyl-CoA:cholesterol O-acyltransferase and low-density lipoprotein receptor expression.
Shigehiro Asano
,
Hitoshi Ban
,
K. Kino
,
K. Ioriya
,
M. Muraoka
Bioorganic & Medicinal Chemistry Letters
2009
Corpus ID: 39763501
Highly Cited
2007
Highly Cited
2007
ACAT inhibitor pactimibe sulfate (CS-505) reduces and stabilizes atherosclerotic lesions by cholesterol-lowering and direct effects in apolipoprotein E-deficient mice.
N. Terasaka
,
A. Miyazaki
,
+7 authors
T. Inaba
Atherosclerosis
2007
Corpus ID: 23756136
2006
2006
Importance of acyl-coenzyme A:cholesterol acyltransferase 1/2 dual inhibition for anti-atherosclerotic potency of pactimibe.
K. Kitayama
,
Tatsuo Tanimoto
,
T. Koga
,
N. Terasaka
,
T. Fujioka
,
T. Inaba
European Journal of Pharmacology
2006
Corpus ID: 20039075
Review
2005
Review
2005
Inhibitors of acyl-coenzyme a: cholesterol acyltransferase.
A. Miyazaki
,
T. Kanome
,
Takuya Watanabe
Current drug targets. Cardiovascular…
2005
Corpus ID: 45048524
Acyl-coenzyme A: cholesterol acyltransferase (ACAT) is an intracellular enzyme that catalyzes the formation of cholesterol esters…
Expand
2005
2005
Systemic Acyl-CoA:Cholesterol Acyltransferase Inhibition Reduces Inflammation and Improves Vascular Function in Hypercholesterolemia
R. Kharbanda
,
S. Wallace
,
B. Walton
,
A. Donald
,
J. Cross
,
J. Deanfield
Circulation
2005
Corpus ID: 3137574
Background—Circulating lipids may initiate and progress atherosclerosis by causing vascular inflammation. Monocytes and tissue…
Expand
Review
2003
Review
2003
New drugs for the treatment of hypercholesterolaemia
P. Iglesias
,
J. Díez
Expert Opinion on Investigational Drugs
2003
Corpus ID: 25316100
Endogenous and exogenous pathways determine plasma levels of cholesterol and lipoproteins. Plasma cholesterol levels and coronary…
Expand
Review
2002
Review
2002
Avasimibe Pfizer.
John R Burnett
,
Murray W Huff
Current opinion in investigational drugs
2002
Corpus ID: 37378623
Avasimibe (also known as CI-1011 or PD-148515) is a selective acyl-coenzyme A:cholesterol O-acyltransferase (ACAT) inhibitory…
Expand
2002
2002
Intracellular mechanisms mediating the inhibition of apoB-containing lipoprotein synthesis and secretion in HepG2 cells by avasimibe (CI-1011), a novel acyl-coenzyme A: cholesterol acyltransferase…
C. Taghibiglou
,
S. C. Van Iderstine
,
Agnes Kulinski
,
D. Rudy
,
K. Adeli
Biochemical Pharmacology
2002
Corpus ID: 37216793
2002
2002
Avasimibe and atorvastatin synergistically reduce cholesteryl ester content in THP-1 macrophages.
G. Llaverías
,
M. Jové
,
+5 authors
M. Alegret
European Journal of Pharmacology
2002
Corpus ID: 10713612
Review
2001
Review
2001
Therapies on the horizon for cholesterol reduction
W. Brown
Clinical Cardiology
2001
Corpus ID: 19884502
Summary: Statins are powerful agents for the reduction of low‐density lipoprotein cholesterol (LDL‐C) and reduction of…
Expand
By clicking accept or continuing to use the site, you agree to the terms outlined in our
Privacy Policy
(opens in a new tab)
,
Terms of Service
(opens in a new tab)
, and
Dataset License
(opens in a new tab)
ACCEPT & CONTINUE